The monoclonal antibodies anti-programmed death protein-1 (anti–PD-1) nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for treatment of recurrent/metastatic (R/M) HNSCC. The gene discussed is SNCA; the disease is head and neck squamous cell carcinoma.